Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023
Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...